Charles Schwab Investment Management Inc. Boosts Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 185,038 shares of the company's stock after acquiring an additional 5,258 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.66% of Krystal Biotech worth $22,956,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Krystal Biotech by 40.7% during the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company's stock valued at $278,416,000 after buying an additional 693,852 shares during the period. Jennison Associates LLC increased its holdings in Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company's stock valued at $89,862,000 after buying an additional 383,495 shares during the period. Fred Alger Management LLC increased its holdings in Krystal Biotech by 4,608.6% during the third quarter. Fred Alger Management LLC now owns 167,485 shares of the company's stock valued at $19,428,000 after buying an additional 163,928 shares during the period. TimesSquare Capital Management LLC purchased a new position in Krystal Biotech during the third quarter valued at approximately $14,272,000. Finally, Schonfeld Strategic Advisors LLC increased its holdings in Krystal Biotech by 356.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 83,635 shares of the company's stock valued at $9,702,000 after buying an additional 65,325 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

KRYS has been the topic of several research reports. HC Wainwright reissued a "buy" rating and set a $200.00 price objective on shares of Krystal Biotech in a report on Monday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a "buy" rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Guggenheim lifted their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $177.63.

Krystal Biotech Trading Down 0.5 %

Shares of NASDAQ:KRYS traded down $0.79 on Friday, hitting $162.83. 144,963 shares of the company were exchanged, compared to its average volume of 271,134. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $189.97. The stock's 50 day moving average price is $166.73 and its 200 day moving average price is $138.21. The firm has a market capitalization of $4.65 billion, a P/E ratio of 87.08 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. During the same period in the prior year, the firm earned ($1.76) EPS. The company's revenue for the quarter was up 452400.0% on a year-over-year basis. On average, equities analysts predict that Krystal Biotech, Inc. will post 2.06 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction on Monday, February 26th. The shares were sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the completion of the transaction, the chief accounting officer now directly owns 12,556 shares of the company's stock, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,087 shares of company stock worth $9,493,191. Company insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).